Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints

Version 1 : Received: 27 October 2020 / Approved: 28 October 2020 / Online: 28 October 2020 (10:02:34 CET)

How to cite: AL-SHABEEB AKIL, A.; Al-Maraghi, A.; YASSIN, E.; AL-MALKI, K.; FAKHRO, K. Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints. Preprints 2020, 2020100578 (doi: 10.20944/preprints202010.0578.v1). AL-SHABEEB AKIL, A.; Al-Maraghi, A.; YASSIN, E.; AL-MALKI, K.; FAKHRO, K. Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints. Preprints 2020, 2020100578 (doi: 10.20944/preprints202010.0578.v1).

Abstract

Type 1 diabetes affects millions of people globally and requires careful management to avoid serious long-term complications, including heart and kidney disease, stroke, and loss of sight. The present standard-of-care for type 1 diabetes is exogenic insulin substitutional therapy. The most advanced stretegies in this area is the development of hybrid-closed loop system and the producing of long-acting insulins. Progresses in stem cell therapies have started to revolutionize the care of patients with type 1 diabetes; however, significant challenges remain including the limited islets availability, difficulties in maintaining the viability, the heterogeneity within a complex pathology and in patients’ responses to treatment. On the way, a considerable amount of efforts in maximizing the islet transplantation effectiveness by controlling the advantageous of different stem cell approaches. With the availability and the use of big data, the concept of precision medicine is gaining wide attention worldwide and could bring the dream of “presonlaized” therapies as a reality in the near future. Here we review the current range of treatments available as well as recent pre-clinical breakthroughs in the field of personlaized medicine for type 1 diabetes.

Subject Areas

Type 1 diabetes; insulin therapy; C-peptide; islet transplantation, mesenchymal stem cells; induced pluripotent stem cells; pancreatic β cell; gene therapy; β-cell regeneration and reprogramming, type 1 diabetes precision medicine, diabetes personalized care.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.